Efeitos do canabidiol na redução da ansiedade: o que o estado da arte evidencia

Abstract

The Cannabis sativa plant contains active substances such as CBD and tetrahydrocannabinol (THC), with the former being extensively studied for its potential therapeutic effects. Studies suggest that CBD possesses anxiolytic properties, but there is significant variability in dosages and methodologies, making it difficult to draw definitive conclusions about its efficacy and long-term safety. This study aims to methodologically characterize and present the main findings of studies addressing the clinical dynamics of therapeutic CBD use in reducing anxiety levels. The research employs a descriptive and qualitative method, using secondary data collected from 10 scientific articles selected from the PubMed, Scielo, and Google Scholar databases. The following descriptors were used: CBD, anxiety, cannabidiol, study, clinical trial, and the Boolean operator "and." Of the 10 articles analyzed, seven demonstrated the effectiveness of CBD in reducing anxiety symptoms. However, the studies indicated variations in dosages ranging from 150 mg to 800 mg per day and treatment durations from 2 to 15 weeks, with some reporting mild side effects such as fatigue and drowsiness. It is concluded that, despite CBD's therapeutic potential, the lack of methodological standardization and therapeutic dosage guidelines in the studies limits the comparability of results and the establishment of therapeutic protocols. It is recommended that more robust and standardized clinical trials be conducted to evaluate the efficacy of CBD in different types of anxiety disorders and to compare its effects to those of conventional treatments.